Safety and efficacy of rh-Lactoferrin in Diabetic Ulcers

Award Information
Agency:
Department of Health and Human Services
Branch
n/a
Amount:
$715,265.00
Award Year:
2004
Program:
SBIR
Phase:
Phase II
Contract:
4R44AR049961-02
Agency Tracking Number:
AR049961
Solicitation Year:
2004
Solicitation Topic Code:
n/a
Solicitation Number:
PHS2004-2
Small Business Information
AGENNIX, INC.
AGENNIX, INC., 8 GREENWAY PLZ, STE 910, HOUSTON, TX, 77046
Hubzone Owned:
N
Socially and Economically Disadvantaged:
N
Woman Owned:
N
Duns:
n/a
Principal Investigator:
JOSE Engelmayer
(713) 552-1091
JENGELMAYER@AGENNIX.COM
Business Contact:
(713) 552-1091
Research Institution:
n/a
Abstract
DESCRIPTION (provided by applicant): Research Objectives: Determine the safety, pharmacokinetics, pharmacodynamics, and efficacy of topical recombinant human lactoferrin (rhLF) in promoting healing in diabetic ulcers. There are 7.5 million U

* information listed above is at the time of submission.

Agency Micro-sites

US Flag An Official Website of the United States Government